Drug Profile

Research programme - STING TLR9 agonist conjugate - CS Bay Therapeutics

Latest Information Update: 28 Jul 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator CS-Bay Therapeutics
Class Antineoplastics; Drug conjugates
Mechanism of Action STING1 protein stimulants; Toll-like receptor 9 agonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

No development reported Cancer

Most Recent Events

28 Jul 2026 No recent reports of development identified for preclinical development in Cancer in USA (SC)
28 Jun 2022 Pharmacodynamics data from preclinical trial in Cancer released by CS Bay Therapeutics
28 Jun 2022 CS Bay Therapeutics plans to submit Investigational New Drug (IND) application for phase I trial in Cancer in 1Q 2023 (CS Bay Therapeutics pipeline, June 2022)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com